Skip to Main Content

Try STAT+ TODAY

pharmaceutical industry

Most Read

Biotech Adam Feuerstein and Damian Garde

STAT Plus: Q&A: How biotech analysts navigate fickle markets, pushy investors, and ‘vindictive’ CEOs

Politics Erin Mershon

STAT Plus: House poised to pass bill critical for drug industry; the Senate may be a slog

Politics Dylan Scott

STAT Plus: Under fire from Trump, drug industry lands Oval Office meeting on Tuesday

Biotech Meghana Keshavan

STAT Plus: Biopharma expects a lot of M&A this year

Politics Dylan Scott

The drug industry’s stake in Trumpcare is bigger than you think

Business Associated Press

Drug prices don’t budge even after pressure from Congress

First Opinion Dana P. Goldman and Darius Lakdawalla

Election verdict: Pharma needs a new prescription

Politics Dylan Scott

Big Pharma’s big question: Is Trump friend or foe?

All Coverage

First Opinion Henry A. Waxman and Bill Corr

Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs

Pharmalot Ed Silverman

The curious case of the $9,500 skin gel

advertisement

Business Damian Garde

STAT Plus: The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes

Politics Dylan Scott

Donald Trump’s trade talk is making the drug industry uneasy

Politics Sheila Kaplan

5 ways drug makers and the health care industry are shaping campaigns

In the Lab Helen Branswell

The race for a Zika vaccine is intense. But it may be missing the most important players

Don't Miss Damian Garde

How biotech executives profit from legal insider trades

Biotech Damian Garde

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

The Pharmalot View Ed Silverman

The ‘gouge factor’: Big companies want transparency in drug price negotiations

Business Rebecca Robbins

Why Democratic convention viewers saw so many drug ads

First Opinion Charles D. Rosen

Say what you will about Donald Trump. He’s right about drug companies

Don't Miss Dylan Scott

Billionaire businessman Mark Cuban has something to say about drug prices

Biotech Damian Garde

Could a molecular ‘on-off switch for agony’ lead to a safer painkiller?

Business Charles Ornstein and Ryann Grochowski Jones — ProPublica

Drug and device makers find receptive audience at for-profit, Southern hospitals

The Pharmalot View Ed Silverman

Drug industry overstates impact of patent reviews on innovation

Biotech Meghana Keshavan and Rebecca Robbins

Post-Brexit, will the European Medicines Agency be homeless?

Politics Dylan Scott

Supreme Court’s ruling in patent case a blow to drug industry